Evaluation of Asymptomatic Coronary Atherosclerotic Disease Among People of Kalamazoo, MI (ESCAPE MI)
Primary Purpose
Coronary Artery Disease, Atherosclerosis
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Computed Tomography (CT) Scan
Sponsored by
About this trial
This is an interventional diagnostic trial for Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria:
- Subject is between 35 and 55 years of age.
- Subject receives care in Kalamazoo County and neighboring areas.
- No known history of coronary artery disease, peripheral vascular disease or stroke.
- Asymptomatic per shortened World Health Organization (WHO) Rose Angina Questionnaire.
Any one of the following sets of clinical risk factors for CAD:
- Premature Immediate Family History of CAD (Male <55 years old, Female <65 years old)
- Diabetes Mellitus Type 2
- Chronic Smoker (currently smoking at least 1 cigarette per month)
- Any family history of CAD with Dyslipidemia or hypertension or former smoker
- Stress test or cardiac catheterization procedure is not clinically indicated for the subject at the time of enrollment.
- Subject has signed informed consent.
Exclusion Criteria:
- Subject has known coronary artery disease.
- Known abnormal stress test where coronary angiography is indicated.
- Subject is unable to routinely walk at least 20 feet without assistance (e.g., requires a walker or wheelchair to mobilize or has known paralysis).
- Subject reports they have active systemic or cutaneous infection or inflammation (e.g., septicemia at the time of the procedure).
- Subject has uncontrolled hypertension (> 180 mmHg systolic and >110mmHg diastolic).
- Subject presents with hemodynamic instability or is in need of emergent surgery.
- Known contraindications or known severe reaction to iodinated contrast media.
- Known contraindications to beta-blockers.
- Known contraindications to use of sublingual nitroglycerine.
- Subject has history of chronic kidney disease, with a Glomerular Filtration Rate (GFR) of 45 or below.
- Subject has known history of Non-Ischemic Cardiomyopathy (NICMP)
- Subject has a pre-existing severe systemic disease or illness that results in an expected life expectancy of less than 2 years.
- Subject is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.
- Pregnant or lactating subjects.
- Known arrhythmias that does not allow electrocardiogram (ECG) triggering, as determined at the time of CT scan. ECG prior to procedure is not indicated.
- History of a brain tumor; a recent (within the past 6 months) head or brain injury, concussion, epilepsy, or other seizure disorders, severe liver disease, sickle cell anemia, multiple sclerosis, substance abuse, multiple myeloma, pheochromocytoma, or a thyroid disorder.
Sites / Locations
- Borgess Medical CenterRecruiting
Outcomes
Primary Outcome Measures
Estimation of the proportion of people in the Kalamazoo, MI, area who have asymptomatic CAD.
Compare evidence of atherosclerosis or calcification, as evidenced by CT scan, to associated biomarker values.
Secondary Outcome Measures
Full Information
NCT ID
NCT02942342
First Posted
March 31, 2016
Last Updated
August 28, 2020
Sponsor
Borgess Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT02942342
Brief Title
Evaluation of Asymptomatic Coronary Atherosclerotic Disease Among People of Kalamazoo, MI
Acronym
ESCAPE MI
Official Title
Evaluation of Asymptomatic Coronary Atherosclerotic Disease Among People of Kalamazoo County and Neighboring Areas in Michigan, Who Have Risk Factors of Coronary Artery Disease
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 2016 (undefined)
Primary Completion Date
January 2022 (Anticipated)
Study Completion Date
March 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Borgess Research Institute
4. Oversight
5. Study Description
Brief Summary
The primary goal of this study is to determine the prevalence of undiagnosed asymptomatic coronary artery disease (CAD) in Kalamazoo and its neighboring areas using Coronary Computed Tomography (CCTA) and Coronary Artery Calcium Score (CACS) to assess if asymptomatic CAD is widespread enough to warrant implementation of CCTA as a routine screening tool. Additionally, this study will use the CCTA results to evaluate several methods of assessing CAD risk in the asymptomatic population including Framingham Risk Score (FRS) and Reynold's Risk Score, Biomarkers (High sensitivity C-Reactive Protein, Fibrinogen, Vertical Auto Profile, oxidized Low Density Lipoprotein (LDL), Apolipoprotein A1 (ApoA1), Apolipoprotein B1 (ApoB1), Vitamin D, Homocysteine) as well as a large panel of genetic markers of atherosclerosis and dyslipidemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Atherosclerosis
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
240 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Computed Tomography (CT) Scan
Intervention Description
CT Scans will be used as a diagnostic tool for asymptomatic CAD.
Primary Outcome Measure Information:
Title
Estimation of the proportion of people in the Kalamazoo, MI, area who have asymptomatic CAD.
Time Frame
3 years
Title
Compare evidence of atherosclerosis or calcification, as evidenced by CT scan, to associated biomarker values.
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is between 35 and 55 years of age.
Subject receives care in Kalamazoo County and neighboring areas.
No known history of coronary artery disease, peripheral vascular disease or stroke.
Asymptomatic per shortened World Health Organization (WHO) Rose Angina Questionnaire.
Any one of the following sets of clinical risk factors for CAD:
Premature Immediate Family History of CAD (Male <55 years old, Female <65 years old)
Diabetes Mellitus Type 2
Chronic Smoker (currently smoking at least 1 cigarette per month)
Any family history of CAD with Dyslipidemia or hypertension or former smoker
Stress test or cardiac catheterization procedure is not clinically indicated for the subject at the time of enrollment.
Subject has signed informed consent.
Exclusion Criteria:
Subject has known coronary artery disease.
Known abnormal stress test where coronary angiography is indicated.
Subject is unable to routinely walk at least 20 feet without assistance (e.g., requires a walker or wheelchair to mobilize or has known paralysis).
Subject reports they have active systemic or cutaneous infection or inflammation (e.g., septicemia at the time of the procedure).
Subject has uncontrolled hypertension (> 180 mmHg systolic and >110mmHg diastolic).
Subject presents with hemodynamic instability or is in need of emergent surgery.
Known contraindications or known severe reaction to iodinated contrast media.
Known contraindications to beta-blockers.
Known contraindications to use of sublingual nitroglycerine.
Subject has history of chronic kidney disease, with a Glomerular Filtration Rate (GFR) of 45 or below.
Subject has known history of Non-Ischemic Cardiomyopathy (NICMP)
Subject has a pre-existing severe systemic disease or illness that results in an expected life expectancy of less than 2 years.
Subject is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.
Pregnant or lactating subjects.
Known arrhythmias that does not allow electrocardiogram (ECG) triggering, as determined at the time of CT scan. ECG prior to procedure is not indicated.
History of a brain tumor; a recent (within the past 6 months) head or brain injury, concussion, epilepsy, or other seizure disorders, severe liver disease, sickle cell anemia, multiple sclerosis, substance abuse, multiple myeloma, pheochromocytoma, or a thyroid disorder.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kathleen Gross, MD
Phone
(269) 337-4327
Email
kathleen.gross@med.wmich.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vishal Gupta, MD, MPH
Organizational Affiliation
Borgess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Borgess Medical Center
City
Kalamazoo
State/Province
Michigan
ZIP/Postal Code
49080
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kathleen Gross, MD
Phone
269-337-4327
Email
kathleen.gross@med.wmich.edu
First Name & Middle Initial & Last Name & Degree
Vishal Gupta, MD, MPH
First Name & Middle Initial & Last Name & Degree
Azzam Kannan, MD
First Name & Middle Initial & Last Name & Degree
Mark Shaman, MD
First Name & Middle Initial & Last Name & Degree
Marcio Curvello, MD
First Name & Middle Initial & Last Name & Degree
John Hopkins, MD
First Name & Middle Initial & Last Name & Degree
Ronald Zegerius, MD
First Name & Middle Initial & Last Name & Degree
Jesse Duranceau, MD
First Name & Middle Initial & Last Name & Degree
Anna Langerveld, PhD
First Name & Middle Initial & Last Name & Degree
James Springstead, PhD
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Asymptomatic Coronary Atherosclerotic Disease Among People of Kalamazoo, MI
We'll reach out to this number within 24 hrs